Search

Your search keyword '"Nieboer, Peter"' showing total 44 results
Start Over "Nieboer, Peter" Search Limiters Available in Library Collection
44 results on '"Nieboer, Peter"'

1. Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD

Author

Knikman, Jonathan E., Zhai, Qinglian, Lunenburg, Carin A. T. C., Henricks, Linda M., Böhringer, Stefan, van der Lee, Maaike, de Man, Femke M., Offer, Steven M., Shrestha, Shikshya, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L. T., Jeurissen, Frank J. F., Portielje, Johanna E. A., Jansen, Rob L. H., Hamberg, Paul, Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H. W., Mandigers, Caroline M. P. W., van Schaik, Ron H. N., Gelderblom, Hans, Mathijssen, Ron H. J., Schellens, Jan H. M., Cats, Annemieke, Guchelaar, Henk-Jan, and Swen, Jesse J.

Published
2024
Full Text
View/download PDF

2. Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase 3 CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group

Author

van der Kruijssen, D.E.W., primary, Elias, S.G., additional, van de Ven, P.M., additional, van Rooijen, K.L., additional, Lam-Boer, J. ’t, additional, Mol, L., additional, Punt, C.J.A., additional, Sommeijer, D.W., additional, Tanis, P.J., additional, Nielsen, J.D., additional, Yilmaz, M.K., additional, Van Riel, J.M.G.H., additional, Wasowiz-Kemps, D.K., additional, Loosveld, O.J.L., additional, van der Schelling, G.P., additional, de Groot, J.W.B., additional, van Westreenen, H.L., additional, Jakobsen, H.L., additional, Fromm, A.L., additional, Hamberg, P., additional, Verseveld, M., additional, Jaensch, C., additional, Liposits, G.I., additional, van Duijvendijk, P., additional, Hadj, J. Oulad, additional, van der Hoeven, J.A.B., additional, Trajkovic, M., additional, de Wilt, J.H.W., additional, Koopman, M., additional, Vincent, Jeroen, additional, Wegdam, Johannes A., additional, Haberkorn, Brigitte C.M., additional, van der Harst, Erwin, additional, Hendriks, Mathijs P., additional, Schreurs, W.H. (Hermien), additional, Cense, Huib A., additional, Rietbroek, Ron C., additional, Gier, Marie-José de, additional, de Widt-Levert, Louise M., additional, van Breugel, Edwin A., additional, de Vos, Aad I., additional, Brosens, Rebecca P.M., additional, Doornebosch, P.G., additional, de Jongh, Felix E., additional, Vles, Wouter J., additional, den Boer, Marien O., additional, Leijtens, Jeroen W.A., additional, Gelderblom, A.J. (Hans), additional, Peeters, Koen C.M.J., additional, Kuenen, Bart C., additional, Pultrum, Bareld B., additional, van Dodewaard-de Jong, Joyce M., additional, Consten, Esther C.J., additional, van de Wouw, A.J. (Yes), additional, Konsten, J.L.M., additional, Hoekstra, R., additional, Lutke Holzik, Martijn F., additional, Vos, Allert H., additional, van Hoogstraten, M.J., additional, Schlesinger, Nis H., additional, Creemers, Geert-Jan, additional, de Hingh, Ignace H.J.T., additional, Kjær, Monica L., additional, Petersen, Lone N., additional, Seiersen, Michael, additional, Altaf, Rahim, additional, van Cruijsen, Hester, additional, HessL, Daniël A., additional, van Leeuwen-Snoeks, obke L., additional, Pronk, Apollo, additional, Baeten, Coen I.M., additional, van der Deure, Wendy M., additional, Bosscha, Koop, additional, Schut, Heidi, additional, Leclercq, W.K.G., additional, Simkens, L.H.J., additional, Reijnders, Koen, additional, van Arkel, Kees, additional, van Grevenstein, W.M.U. (Helma), additional, van de Ven, Anthony W.H., additional, Vuylsteke, Ronald J.C.L.M., additional, Kuijer, Philomeen, additional, Bakker, Sandra D., additional, Goei, Hauwy, additional, Helgason, Helgi H., additional, van Acker, Gijs J.D., additional, Temizkan, Mehmet, additional, van Tilburg, Marc W.A., additional, Gerhards, Michael F., additional, Kerver, E.D., additional, Gootjes, Elske, additional, Nieboer, Peter, additional, Bleeker, Wim A., additional, and Vink, G.R., additional

Published
2024
Full Text
View/download PDF

3. Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD

Author

MS Medische Oncologie, Cancer, Knikman, Jonathan E., Zhai, Qinglian, Lunenburg, Carin A.T.C., Henricks, Linda M., Böhringer, Stefan, van der Lee, Maaike, de Man, Femke M., Offer, Steven M., Shrestha, Shikshya, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., van Schaik, Ron H.N., Gelderblom, Hans, Mathijssen, Ron H.J., Schellens, Jan H.M., Cats, Annemieke, Guchelaar, Henk Jan, Swen, Jesse J., MS Medische Oncologie, Cancer, Knikman, Jonathan E., Zhai, Qinglian, Lunenburg, Carin A.T.C., Henricks, Linda M., Böhringer, Stefan, van der Lee, Maaike, de Man, Femke M., Offer, Steven M., Shrestha, Shikshya, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., van Schaik, Ron H.N., Gelderblom, Hans, Mathijssen, Ron H.J., Schellens, Jan H.M., Cats, Annemieke, Guchelaar, Henk Jan, and Swen, Jesse J.

Published
2024

6. Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer

Author

Smit, Karel C., Derksen, Jeroen W.G., Beets, Geerard L.O., Belt, Eric J.Th, Berbée, Maaike, Coene, Peter Paul L.O., Van Cruijsen, Hester, Davidis, Marjan A., Dekker, Jan Willem T., Van Dodewaard-De Jong, Joyce M., Haringhuizen, Annebeth W., Helgason, Helgi H., Hendriks, Mathijs P., Hoekstra, Ronald, De Hingh, Ignace H.J.T., Ijzermans, Jan N.M., Janssen, Johan J.B., Konsten, Joop L.M., Los, Maartje, Mekenkamp, Leonie J.M., Nieboer, Peter, Peeters, Koen C.M.J., Peters, Natascha A.J.B., Pruijt, Hans J.F.M., Van Ufford-Mannesse, Patricia Quarles, Rietbroek, Ron C., Schiphorst, Anandi H.W., Van Der Velden, Arjan Schouten, Schrauwen, Ruud W.M., Sie, Mark P.S., Sommeijer, Dirkje W., Sonneveld, Dirk J.A., Stockmann, Hein B.A.C., Tent, Marleen, Terheggen, Frederiek, Tjin-A-Ton, Manuel L.R., Valkenburg-Van Iersel, Liselot, Van Der Velden, Ankie M.T., Vles, Wouter J., Van Voorthuizen, Theo, Wegdam, Johannes A., De Wilt, Johannes H.W., Koopman, Miriam, May, Anne M., Smit, Karel C., Derksen, Jeroen W.G., Beets, Geerard L.O., Belt, Eric J.Th, Berbée, Maaike, Coene, Peter Paul L.O., Van Cruijsen, Hester, Davidis, Marjan A., Dekker, Jan Willem T., Van Dodewaard-De Jong, Joyce M., Haringhuizen, Annebeth W., Helgason, Helgi H., Hendriks, Mathijs P., Hoekstra, Ronald, De Hingh, Ignace H.J.T., Ijzermans, Jan N.M., Janssen, Johan J.B., Konsten, Joop L.M., Los, Maartje, Mekenkamp, Leonie J.M., Nieboer, Peter, Peeters, Koen C.M.J., Peters, Natascha A.J.B., Pruijt, Hans J.F.M., Van Ufford-Mannesse, Patricia Quarles, Rietbroek, Ron C., Schiphorst, Anandi H.W., Van Der Velden, Arjan Schouten, Schrauwen, Ruud W.M., Sie, Mark P.S., Sommeijer, Dirkje W., Sonneveld, Dirk J.A., Stockmann, Hein B.A.C., Tent, Marleen, Terheggen, Frederiek, Tjin-A-Ton, Manuel L.R., Valkenburg-Van Iersel, Liselot, Van Der Velden, Ankie M.T., Vles, Wouter J., Van Voorthuizen, Theo, Wegdam, Johannes A., De Wilt, Johannes H.W., Koopman, Miriam, and May, Anne M.

Abstract

Regular physical activity (PA) is associated with improved overall survival (OS) in stage I-III colorectal cancer (CRC) patients. This association is less defined in patients with metastatic CRC (mCRC). We therefore conducted a study in mCRC patients participating in the Prospective Dutch Colorectal Cancer cohort. PA was assessed with the validated SQUASH questionnaire, filled-in within a maximum of 60 days after diagnosis of mCRC. PA was quantified by calculating Metabolic Equivalent Task (MET) hours per week. American College of Sports and Medicine (ACSM) PA guideline adherence, tertiles of moderate to vigorous PA (MVPA), and sport and leisure time MVPA (MVPA-SL) were assessed as well. Vital status was obtained from the municipal population registry. Cox proportional-hazards models were used to study the association between PA determinants and all-cause mortality adjusted for prognostic patient and treatment-related factors. In total, 293 mCRC patients (mean age 62.9±10.6 years, 67% male) were included in the analysis. Compared to low levels, moderate and high levels of MET-hours were significantly associated with longer OS (fully adjusted hazard ratios: 0.491, (95% CI 0.299-0.807, p value=0.005) and 0.485 (95% CI 0.303-0.778, p value=0.003), respectively), as were high levels of MVPA (0.476 (95% CI 0.278-0.816, p value=0.007)) and MVPA-SL (0.389 (95% CI 0.224-0.677, p value<0.001)), and adherence to ACSM PA guidelines compared to non-adherence (0.629 (95% CI 0.412-0.961, p value=0.032)). The present study provides evidence that higher PA levels at diagnosis of mCRC are associated with longer OS.

Published
2022

7. Physical Activity Is Associated with Improved Overall Survival among Patients with Metastatic Colorectal Cancer

Author

Epi Kanker Team B, Cancer, MS Medische Oncologie, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, Smit, Karel C, Derksen, Jeroen W G, Beets, Geerard L O, Belt, Eric J Th, Berbée, Maaike, Coene, Peter Paul L O, van Cruijsen, Hester, Davidis, Marjan A, Dekker, Jan Willem T, van Dodewaard-de Jong, Joyce M, Haringhuizen, Annebeth W, Helgason, Helgi H, Hendriks, Mathijs P, Hoekstra, Ronald, de Hingh, Ignace H J T, IJzermans, Jan N M, Janssen, Johan J B, Konsten, Joop L M, Los, Maartje, Mekenkamp, Leonie J M, Nieboer, Peter, Peeters, Koen C M J, Peters, Natascha A J B, Pruijt, Hans J F M, Quarles van Ufford-Mannesse, Patricia, Rietbroek, Ron C, Schiphorst, Anandi H W, Schouten van der Velden, Arjan, Schrauwen, Ruud W M, Sie, Mark P S, Sommeijer, Dirkje W, Sonneveld, Dirk J A, Stockmann, Hein B A C, Tent, Marleen, Terheggen, Frederiek, Tjin-A-Ton, Manuel L R, Valkenburg-van Iersel, Liselot, van der Velden, Ankie M T, Vles, Wouter J, van Voorthuizen, Theo, Wegdam, Johannes A, de Wilt, Johannes H W, Koopman, Miriam, May, Anne M, On Behalf Of The Plcrc Study Group, Epi Kanker Team B, Cancer, MS Medische Oncologie, Epidemiology & Health Economics, JC onderzoeksprogramma Kanker, Smit, Karel C, Derksen, Jeroen W G, Beets, Geerard L O, Belt, Eric J Th, Berbée, Maaike, Coene, Peter Paul L O, van Cruijsen, Hester, Davidis, Marjan A, Dekker, Jan Willem T, van Dodewaard-de Jong, Joyce M, Haringhuizen, Annebeth W, Helgason, Helgi H, Hendriks, Mathijs P, Hoekstra, Ronald, de Hingh, Ignace H J T, IJzermans, Jan N M, Janssen, Johan J B, Konsten, Joop L M, Los, Maartje, Mekenkamp, Leonie J M, Nieboer, Peter, Peeters, Koen C M J, Peters, Natascha A J B, Pruijt, Hans J F M, Quarles van Ufford-Mannesse, Patricia, Rietbroek, Ron C, Schiphorst, Anandi H W, Schouten van der Velden, Arjan, Schrauwen, Ruud W M, Sie, Mark P S, Sommeijer, Dirkje W, Sonneveld, Dirk J A, Stockmann, Hein B A C, Tent, Marleen, Terheggen, Frederiek, Tjin-A-Ton, Manuel L R, Valkenburg-van Iersel, Liselot, van der Velden, Ankie M T, Vles, Wouter J, van Voorthuizen, Theo, Wegdam, Johannes A, de Wilt, Johannes H W, Koopman, Miriam, May, Anne M, and On Behalf Of The Plcrc Study Group

Published
2022

8. The Prospective Dutch Colorectal Cancer (PLCRC) cohort: real-world data facilitating research and clinical care

Author

Derksen, Jeroen W. G., Vink, Geraldine R., Elferink, Marloes A. G., Roodhart, Jeanine M. L., Verkooijen, Helena M., van Grevenstein, Wilhelmina M. U., Siersema, Peter D., May, Anne M., Koopman, Miriam, Beets, Geerard L., Belt, Eric J. Th., Berbée, Maaike, Beverdam, Frederique H., Blankenburgh, Ruud, Coene, Peter Paul L. O., van Cruijsen, Hester, Dekker, Jan Willem T., van Dodewaard-de Jong, Joyce M., Erdkamp, Frans L. G., de Groot, Jan Willem B., Haringhuizen, Annebeth W., Helgason, Helgi H., Hendriks, Mathijs P., de Hingh, Ignace H. J. T., Hoekstra, Ronald, Ijzermans, Jan N. M., Jansen, Jan, Kloppenberg, Frank W. H., van Lent, Anja U. G., Los, Maartje, Meijerink, Martijn R., Mekenkamp, Leonie J. M., Nieboer, Peter, Peeters, Koen C. M. J., Peters, Natascha A. J. B., Polée, Marco B., Pruijt, Johannes F. M., Punt, Cornelis J. A., van Ufford-Mannesse, Patricia Quarles, Rietbroek, Ron C., Schiphorst, Anandi H. W., van der Velden, Arjan Schouten, Schrauwen, Ruud W. M., Sie, Mark P. S., Simkens, Lieke, Sommeijer, Dirkje W., Sonneveld, Dirk J. A., Spierings, Leontine E. A., Stockmann, Hein B. A. C., Talsma, Koen, Terheggen, Frederiek, ten Tije, Albert J., Tjin-A-Ton, Manuel L. R., Valkenburg-van Iersel, Liselot B. J., Veenstra, Renzo P., van der Velden, Ankie M. T., Vermaas, Maarten, Vles, Wouter J., Vogelaar, Jeroen F. J., van Voorthuizen, Theo, de Vos, Aad I., Wegdam, Johannes A., de Wilt, Johannes H. W., Zimmerman, David D. E., Surgery, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Epidemiologie, CCA - Cancer Treatment and quality of life, Radiology and nuclear medicine, Internal medicine, and VU University medical center

Subjects
Male, medicine.medical_specialty, Colorectal cancer, Epidemiology, Science, Population, MODELS, MEDLINE, Logistic regression, Representativeness heuristic, Article, 03 medical and health sciences, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 0302 clinical medicine, Cancer epidemiology, Medical research, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Multidisciplinary approach, COLON, medicine, Humans, 030212 general & internal medicine, Prospective Studies, Registries, education, Aged, Netherlands, Aged, 80 and over, education.field_of_study, Multidisciplinary, business.industry, Middle Aged, medicine.disease, Cancer registry, TRIALS, Outcomes research, 030220 oncology & carcinogenesis, Family medicine, Cohort, Medicine, Female, business, Colorectal Neoplasms
Abstract

Real-world data (RWD) sources are important to advance clinical oncology research and evaluate treatments in daily practice. Since 2013, the Prospective Dutch Colorectal Cancer (PLCRC) cohort, linked to the Netherlands Cancer Registry, serves as an infrastructure for scientific research collecting additional patient-reported outcomes (PRO) and biospecimens. Here we report on cohort developments and investigate to what extent PLCRC reflects the “real-world”. Clinical and demographic characteristics of PLCRC participants were compared with the general Dutch CRC population (n = 74,692, Dutch-ref). To study representativeness, standardized differences between PLCRC and Dutch-ref were calculated, and logistic regression models were evaluated on their ability to distinguish cohort participants from the Dutch-ref (AU-ROC 0.5 = preferred, implying participation independent of patient characteristics). Stratified analyses by stage and time-period (2013–2016 and 2017–Aug 2019) were performed to study the evolution towards RWD. In August 2019, 5744 patients were enrolled. Enrollment increased steeply, from 129 participants (1 hospital) in 2013 to 2136 (50 of 75 Dutch hospitals) in 2018. Low AU-ROC (0.65, 95% CI: 0.64–0.65) indicates limited ability to distinguish cohort participants from the Dutch-ref. Characteristics that remained imbalanced in the period 2017–Aug’19 compared with the Dutch-ref were age (65.0 years in PLCRC, 69.3 in the Dutch-ref) and tumor stage (40% stage-III in PLCRC, 30% in the Dutch-ref). PLCRC approaches to represent the Dutch CRC population and will ultimately meet the current demand for high-quality RWD. Efforts are ongoing to improve multidisciplinary recruitment which will further enhance PLCRC’s representativeness and its contribution to a learning healthcare system.

Published
2021

9. Perceptions of involvement in advance care planning and emotional functioning in patients with advanced cancer

Author

Kroon, Lente L., Van Roij, Janneke, Korfage, Ida J., Reyners, An K. L., Van Den Beuken-van Everdingen, Marieke H. J., Den Boer, Marien O., Creemers, Geert-jan, De Graeff, Alexander, Hendiks, Mathijs P., Hunting, Jarmo C. B., De Jong, Wouter K., Kuip, Evelien J. M., Van Laarhoven, Hanneke W. M., Van Leeuwen, Lobke, Van Lindert, Anne S. R., Mandigers, Caroline M. P. W., Nieboer, Peter, Van Der Padt-Pruijsten, Annemieke, Smilde, Tineke J., Sommeijer, Dirkje W., Thijs, Martine F., Tiemessen, Marian A., Vos, Allert H., Vreugdenhil, Art, Werner, Philo T., Van Zuylen, Lia, van de Poll-Franse, Lonneke V., Raijmakers, Natasja J. H., Kroon, Lente L., Van Roij, Janneke, Korfage, Ida J., Reyners, An K. L., Van Den Beuken-van Everdingen, Marieke H. J., Den Boer, Marien O., Creemers, Geert-jan, De Graeff, Alexander, Hendiks, Mathijs P., Hunting, Jarmo C. B., De Jong, Wouter K., Kuip, Evelien J. M., Van Laarhoven, Hanneke W. M., Van Leeuwen, Lobke, Van Lindert, Anne S. R., Mandigers, Caroline M. P. W., Nieboer, Peter, Van Der Padt-Pruijsten, Annemieke, Smilde, Tineke J., Sommeijer, Dirkje W., Thijs, Martine F., Tiemessen, Marian A., Vos, Allert H., Vreugdenhil, Art, Werner, Philo T., Van Zuylen, Lia, van de Poll-Franse, Lonneke V., and Raijmakers, Natasja J. H.

Abstract

Purpose Advance Care Planning (ACP) is positively associated with the quality of care, but its impact on emotional functioning is ambiguous. This study investigated the association between perceptions of ACP involvement and emotional functioning in patients with advanced cancer. Methods This study analyzed baseline data of 1,001 patients of the eQuiPe study, a prospective, longitudinal, multicenter, observational study on quality of care and quality of life in patients with advanced cancer in the Netherlands. Patients with metastatic solid cancer were asked to participate between November 2017 and January 2020. Patients’ perceptions of ACP involvement were measured by three self-administered statements. Emotional functioning was measured by the EORTC-QLQ-C30. A linear multivariable regression analysis was performed while taking gender, age, migrant background, education, marital status, and symptom burden into account. Results The majority of patients (87%) reported that they were as much involved as they wanted to be in decisions about their future medical treatment and care. Most patients felt that their relatives (81%) and physicians (75%) were familiar with their preferences for future medical treatment and care. A positive association was found between patients’ perceptions of ACP involvement and their emotional functioning (b=0.162, p<0.001, 95%CI[0.095;0.229]) while controlling for relevant confounders. Conclusions Perceptions of involvement in ACP are positively associated with emotional functioning in patients with advanced cancer. Future studies are needed to further investigate the effect of ACP on emotional functioning. Trial registration number NTR6584 Date of registration: 30 June 2017 Implications for Cancer Survivors Patients’ emotional functioning might improve from routine discussions regarding goals of future care. Therefore, integration of ACP into palliative might be promisi

Published
2021

10. Prospective cohort study of patients with advanced cancer and their relatives on the experienced quality of care and life (eQuiPe study): A study protocol

Author

van Roij, Janneke, Zijlstra, Myrte, Ham, Laurien, Brom, Linda, Fransen, Heidi, Vreugdenhil, Art, Raijmakers, Natasja, van de Poll-Franse, Lonneke, Youssef-Elsoud, Maggy, Creemers, Geert-Jan, van den Borne, Ben, de Jong, Wouter, Baars, Arnold, van den Beuken - van Everdingen, Marieke, Kuip, Evelien, Bunnik, René, Hendriks, Mathijs, Mandigers, Caroline, van Basten, Jean-Paul, van Kampen - van den Boogaart, Vivian, Werner, Philo, van Zuylen, Lia, de Graeff, Alexander, van Lindert, Anne, Soesan, Marcel, Hunting, Jarmo, Smals, Arno, van de Winkel, Linda, Stege, Gerben, Verhaert, Liese, Peters, Natascha, Pepels, Manon, Smilde, Tineke, Nieboer, Peter, de Hosson, Sander, den Boer, Marien, Pitz, Cordula, Heyne, Rick, Tjin-A-Ton, Manuel, van der Padt - Pruijsten, Annemieke, van den Berg, Paul, Krouwels, Frans, van Leeuwen-Snoeks, Lobke, van der Meer, Femke, Vos, Allert, Veldhuis, Gerrit Jan, Poppema, Boelo, Thijs-Visser, Martine, Heller-Baan, Roxane, van Laren, Marjolein, van den Brink, Karen Maassen, Douma, Gea, Kloover, Jeroen, Sommeijer, Dirkje, Pronk, Lemke, Janssens - van Vliet, Ellen, van der Velden, Lilly-Ann, Hafkamp, Emma, Codrington, Henk, Tarasevych, Svitlana, van Bochove, Aart, de Boer, Jaap, Vink, Geraldine, Oncology, Medical and Clinical Psychology, Internal medicine, CCA - Cancer Treatment and quality of life, and VU University medical center

Subjects
Adult, Quality of life, medicine.medical_specialty, Palliative care, Population, lcsh:Special situations and conditions, Disease, Cohort Studies, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 03 medical and health sciences, 0302 clinical medicine, Clinical Protocols, Neoplasms, Surveys and Questionnaires, Advanced cancer, Study protocol, Humans, Medicine, Family, Longitudinal Studies, Prospective Studies, 030212 general & internal medicine, Prospective study, education, Prospective cohort study, Netherlands, Quality of Health Care, Terminal Care, education.field_of_study, business.industry, lcsh:RC952-1245, Quality of care, General Medicine, Relatives, Cancer registry, Longitudinal cohort study, 030220 oncology & carcinogenesis, Family medicine, Population study, business, Cohort study
Abstract

Background Palliative care is becoming increasingly important because the number of patients with an incurable disease is growing and their survival is improving. Previous research tells us that early palliative care has the potential to improve quality of life (QoL) in patients with advanced cancer and their relatives. According to limited research on palliative care in the Netherlands, patients with advanced cancer and their relatives find current palliative care suboptimal. The aim of the eQuiPe study is to understand the experienced quality of care (QoC) and QoL of patients with advanced cancer and their relatives to further improve palliative care. Methods A prospective longitudinal observational cohort study is conducted among patients with advanced cancer and their relatives. Patients and relatives receive a questionnaire every 3 months regarding experienced QoC and QoL during the palliative trajectory. Bereaved relatives receive a final questionnaire 3 to 6 months after the patients’ death. Data from questionnaires are linked with detailed clinical data from the Netherlands Cancer Registry (NCR). By means of descriptive statistics we will examine the experienced QoC and QoL in our study population. Differences between subgroups and changes over time will be assessed while adjusting for confounding factors. Discussion This study will be the first to prospectively and longitudinally explore experienced QoC and QoL in patients with advanced cancer and their relatives simultaneously. This study will provide us with population-based information in patients with advanced cancer and their relatives including changes over time. Results from the study will inform us on how to further improve palliative care. Trial registration Trial NL6408 (NTR6584). Registered in Netherlands Trial Register on June 30, 2017.

Published
2020

11. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): Study protocol for a trial within a cohort study

Author

Schraa, S. J., Van Rooijen, K. L., Van Der Kruijssen, D. E.W., Rubio Alarcón, C., Phallen, J., Sausen, M., Simmons, J., Coupé, V. M.H., Van Grevenstein, W. M.U., Elias, S., Verkooijen, H. M., Laclé, M. M., Bosch, L. J.W., Van Den Broek, D., Meijer, G. A., Velculescu, V. E., Fijneman, R. J.A., Vink, G. R., Koopman, M., Dunker, Mich S., Lutke Holzik, Martijn F., Hoekstra, Ronald, Sommeijer, Dirkje W., Van Der Bilt, Jarmila D.W., Consten, Esther C.J., Cirkel, Geert A., Burghgraef, Thijs A., Van Der Schans, Emma M., Nieboer, Peter, Rietbroek, Ron C., Dekker, Jan Willem T., Verschoor, Arjan J., Talsma, Koen A.K., Brosens, Rebecca P.M., Helgason, Helgi H., Marinelli, Andreas W.K.S., De Hingh, Ignace H.J.T., Oldenhuis, Corina N., Jansen, Jan, Van Halteren, Henk K., Stockmann, Hein B.A.C., Beeker, Aart, Bosscha, Koop, Pruijt, Hans F.M., Spierings, Leontine E.A.M.M., Valkenburg-Van Iersel, Liselot B.J., Vles, Wouter J., De Jongh, Felix E., Van Cruijsen, Hester, Heikens, Joost T., Zimmerman, David D.E., Van Alphen, Robert J., Schiphorst, Anandi H.W., Van Leeuwen-Snoeks, Lobke L., Vogelaar, Jeroen F.J., Peters, Natascha A.J.B., Epidemiology and Data Science, APH - Methodology, CCA - Cancer Treatment and quality of life, Pathology, Internal medicine, Orthopedic Surgery and Sports Medicine, VU University medical center, Surgery, ​Robotics and image-guided minimally-invasive surgery (ROBOTICS), RS: NUTRIM - R3 - Respiratory & Age-related Health, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, MUMC+: MA Medische Oncologie (9), Medical Biology, Nephrology, and Oncology

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, Neoplasm, Residual, Colorectal cancer, Cost-Benefit Analysis, COLORECTAL-CANCER, Circulating Tumor DNA, Study Protocol, 0302 clinical medicine, RESIDUAL DISEASE, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Prospective Studies, Colectomy, Netherlands, Randomized Controlled Trials as Topic, RISK, education.field_of_study, RANDOMIZED CONTROLLED-TRIAL, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Colon cancer, Oxaliplatin, Chemotherapy, Adjuvant, CELL-FREE DNA, 030220 oncology & carcinogenesis, Colonic Neoplasms, Practice Guidelines as Topic, SURVIVAL, Female, medicine.drug, Cohort study, Adult, medicine.medical_specialty, Population, TwiCs, lcsh:RC254-282, Disease-Free Survival, LEUCOVORIN, Capecitabine, 03 medical and health sciences, Internal medicine, Genetics, medicine, Biomarkers, Tumor, Humans, RECURRENCE, education, Neoplasm Staging, Intention-to-treat analysis, business.industry, Liquid Biopsy, ctDNA, Patient Acceptance of Health Care, medicine.disease, Minimal residual disease, FLUOROURACIL, Adjuvant chemotherapy, 030104 developmental biology, Quality of Life, Neoplasm Recurrence, Local, business, Follow-Up Studies
Abstract

Background Accurate detection of patients with minimal residual disease (MRD) after surgery for stage II colon cancer (CC) remains an urgent unmet clinical need to improve selection of patients who might benefit form adjuvant chemotherapy (ACT). Presence of circulating tumor DNA (ctDNA) is indicative for MRD and has high predictive value for recurrent disease. The MEDOCC-CrEATE trial investigates how many stage II CC patients with detectable ctDNA after surgery will accept ACT and whether ACT reduces the risk of recurrence in these patients. Methods/design MEDOCC-CrEATE follows the ‘trial within cohorts’ (TwiCs) design. Patients with colorectal cancer (CRC) are included in the Prospective Dutch ColoRectal Cancer cohort (PLCRC) and give informed consent for collection of clinical data, tissue and blood samples, and consent for future randomization. MEDOCC-CrEATE is a subcohort within PLCRC consisting of 1320 stage II CC patients without indication for ACT according to current guidelines, who are randomized 1:1 into an experimental and a control arm. In the experimental arm, post-surgery blood samples and tissue are analyzed for tissue-informed detection of plasma ctDNA, using the PGDx elio™ platform. Patients with detectable ctDNA will be offered ACT consisting of 8 cycles of capecitabine plus oxaliplatin while patients without detectable ctDNA and patients in the control group will standard follow-up according to guideline. The primary endpoint is the proportion of patients receiving ACT when ctDNA is detectable after resection. The main secondary outcome is 2-year recurrence rate (RR), but also includes 5-year RR, disease free survival, overall survival, time to recurrence, quality of life and cost-effectiveness. Data will be analyzed by intention to treat. Discussion The MEDOCC-CrEATE trial will provide insight into the willingness of stage II CC patients to be treated with ACT guided by ctDNA biomarker testing and whether ACT will prevent recurrences in a high-risk population. Use of the TwiCs design provides the opportunity to randomize patients before ctDNA measurement, avoiding ethical dilemmas of ctDNA status disclosure in the control group. Trial registration Netherlands Trial Register: NL6281/NTR6455. Registered 18 May 2017, https://www.trialregister.nl/trial/6281

Published
2020

19. Additional file 3 of Effects of oncological care pathways in primary and secondary care on patient, professional and health systems outcomes: a systematic review and meta-analysis

Author

Hoeve, Jolanda C. Van, Vernooij, Robin W. M., Fiander, Michelle, Nieboer, Peter, Siesling, Sabine, and Rotter, Thomas

Subjects
technology, industry, and agriculture, lipids (amino acids, peptides, and proteins)
Abstract

Additional file 3. Systematic review cancer care pathways PRISMA flow diagram.

Published
2020
Full Text
View/download PDF

20. Patients’ perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict

Author

Cancer, Pathologie Groep Van Diest, Onderzoek Beeld, Pathologie, van Steenhoven, Julia E.C., den Dekker, Bianca M., Kuijer, Anne, van Diest, Paul J., Nieboer, Peter, Zuetenhorst, Johanna M., Imholz, Alex L.Th, Siesling, Sabine, van Dalen, Thijs, Cancer, Pathologie Groep Van Diest, Onderzoek Beeld, Pathologie, van Steenhoven, Julia E.C., den Dekker, Bianca M., Kuijer, Anne, van Diest, Paul J., Nieboer, Peter, Zuetenhorst, Johanna M., Imholz, Alex L.Th, Siesling, Sabine, and van Dalen, Thijs

Published
2020

22. The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer

Author

Onderzoek Medische Oncologie, Cancer, Arts-assistenten Radiotherapie, JC onderzoeksprogramma Kanker, Epi Kanker Team 1, Epi Kanker Team A, MS Medische Oncologie, Epidemiology & Health Economics, Derksen, Jeroen W G, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, Jourdan, Marion, van der Velden, Ankie M T, Nieboer, Peter, de Jong, Robert S, Honkoop, Aafke H, Punt, Cornelis J A, Koopman, Miriam, May, Anne M, Onderzoek Medische Oncologie, Cancer, Arts-assistenten Radiotherapie, JC onderzoeksprogramma Kanker, Epi Kanker Team 1, Epi Kanker Team A, MS Medische Oncologie, Epidemiology & Health Economics, Derksen, Jeroen W G, Kurk, Sophie A, Peeters, Petra H M, Dorresteijn, Bram, Jourdan, Marion, van der Velden, Ankie M T, Nieboer, Peter, de Jong, Robert S, Honkoop, Aafke H, Punt, Cornelis J A, Koopman, Miriam, and May, Anne M

Published
2020

23. The association between changes in muscle mass and quality of life in patients with metastatic colorectal cancer

Author

Derksen, Jeroen W.G., primary, Kurk, Sophie A., additional, Peeters, Petra H.M., additional, Dorresteijn, Bram, additional, Jourdan, Marion, additional, Velden, Ankie M.T., additional, Nieboer, Peter, additional, Jong, Robert S., additional, Honkoop, Aafke H., additional, Punt, Cornelis J.A., additional, Koopman, Miriam, additional, and May, Anne M., additional

Published
2020
Full Text
View/download PDF

24. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy

Author

Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, van Werkhoven, Erik, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, Schellens, Jan H M, Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, van Werkhoven, Erik, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, and Schellens, Jan H M

Abstract

BACKGROUND: Fluoropyrimidine therapy including capecitabine or 5-fluorouracil can result in severe treatment-related toxicity in up to 30% of patients. Toxicity is often related to reduced activity of dihydropyrimidine dehydrogenase, the main metabolic fluoropyrimidine enzyme, primarily caused by genetic DPYD polymorphisms. In a large prospective study, it was concluded that upfront DPYD-guided dose individualisation is able to improve safety of fluoropyrimidine-based therapy. In our current analysis, we evaluated whether this strategy is cost saving.METHODS: A cost-minimisation analysis from a health-care payer perspective was performed as part of the prospective clinical trial (NCT02324452) in which patients prior to start of fluoropyrimidine-based therapy were screened for the DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A and received an initial dose reduction of 25% (c.2846A>T, c.1236G>A) or 50% (DPYD*2A, c.1679T>G). Data on treatment, toxicity, hospitalisation and other toxicity-related interventions were collected. The model compared prospective screening for these DPYD variants with no DPYD screening. One-way and probabilistic sensitivity analyses were also performed.RESULTS: Expected total costs of the screening strategy were €2599 per patient compared with €2650 for non-screening, resulting in a net cost saving of €51 per patient. Results of the probabilistic sensitivity and one-way sensitivity analysis demonstrated that the screening strategy was very likely to be cost saving or worst case cost-neutral.CONCLUSIONS: Upfront DPYD-guided dose individualisation, improving patient safety, is cost saving or cost-neutral but is not expected to yield additional costs. These results endorse implementing DPYD screening before start of fluoropyrimidine treatment as standard of care.

Published
2019

25. A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

Author

Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., van Werkhoven, Erik, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, Schellens, Jan H.M., Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., van Werkhoven, Erik, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, and Schellens, Jan H.M.

Published
2019

26. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, van Werkhoven, Erik, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, Schellens, Jan H M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, van Werkhoven, Erik, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, and Schellens, Jan H M

Published
2019

27. A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

Author

Apotheek Opleiding, UMC Utrecht, HEE, Child Health, JC onderzoeksprogramma Methodologie, MS Medische Oncologie, Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., van Werkhoven, Erik, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, Schellens, Jan H.M., Apotheek Opleiding, UMC Utrecht, HEE, Child Health, JC onderzoeksprogramma Methodologie, MS Medische Oncologie, Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., van Werkhoven, Erik, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, and Schellens, Jan H.M.

Published
2019

28. Additional file 2: of Effects of oncological care pathways in primary and secondary care on patient, professional, and health systems outcomes: protocol for a systematic review and meta-analysis

Author

Hoeve, Jolanda Van, Vernooij, Robin, Adegboyega Lawal, Fiander, Michelle, Nieboer, Peter, Siesling, Sabine, and Rotter, Thomas

Subjects
body regions, nervous system, fungi
Abstract

OVID MEDLINE search strategy oncology care pathways review. (PDF 23Â kb)

Published
2018
Full Text
View/download PDF

30. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Author

Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, Werkhoven, Erik van, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, Schellens, Jan H M, Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, Werkhoven, Erik van, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, and Schellens, Jan H M

Abstract

BACKGROUND: Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine dehydrogenase (DPD), mostly caused by genetic variants in the gene encoding DPD (DPYD). We assessed the effect of prospective screening for the four most relevant DPYD variants (DPYD*2A [rs3918290, c.1905+1G>A, IVS14+1G>A], c.2846A>T [rs67376798, D949V], c.1679T>G [rs55886062, DPYD*13, I560S], and c.1236G>A [rs56038477, E412E, in haplotype B3]) on patient safety and subsequent DPYD genotype-guided dose individualisation in daily clinical care.METHODS: In this prospective, multicentre, safety analysis in 17 hospitals in the Netherlands, the study population consisted of adult patients (≥18 years) with cancer who were intended to start on a fluoropyrimidine-based anticancer therapy (capecitabine or fluorouracil as single agent or in combination with other chemotherapeutic agents or radiotherapy). Patients with all tumour types for which fluoropyrimidine-based therapy was considered in their best interest were eligible. We did prospective genotyping for DPYD*2A, c.2846A>T, c.1679T>G, and c.1236G>A. Heterozygous DPYD variant allele carriers received an initial dose reduction of 25% (c.2846A>T and c.1236G>A) or 50% (DPYD*2A and c.1679T>G), and DPYD wild-type patients were treated according to the current standard of care. The primary endpoint of the study was the frequency of severe (National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 grade ≥3) overall fluoropyrimidine-related toxicity across the entire treatment duration. We compared toxicity incidence between DPYD variant allele carriers and DPYD wild-type patients on an intention-to-treat basis, and relative risks (RRs) for severe toxicity were compared between the current study and a historical cohort of DPYD variant allele carriers treated with full dose fluor

Published
2018

31. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer : a prospective safety analysis

Author

Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., Werkhoven, Erik van, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, Schellens, Jan H.M., Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., Werkhoven, Erik van, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, and Schellens, Jan H.M.

Published
2018

32. Conventional pathology versus gene signatures for assessing luminal A and B type breast cancers : Results of a prospective cohort study

Author

van Steenhoven, Julia E.C., Kuijer, Anne, van Diest, Paul J., van Gorp, Joost M., Straver, Marieke, Elias, Sjoerd G., Wesseling, Jelle, Rutgers, Emiel, Timmer-Bonte, Johanna N.H., Nieboer, Peter, Smilde, Tineke J., Imholz, Alex, Blanken, Charlotte F.J.M., Siesling, Sabine, van Dalen, Thijs, van Steenhoven, Julia E.C., Kuijer, Anne, van Diest, Paul J., van Gorp, Joost M., Straver, Marieke, Elias, Sjoerd G., Wesseling, Jelle, Rutgers, Emiel, Timmer-Bonte, Johanna N.H., Nieboer, Peter, Smilde, Tineke J., Imholz, Alex, Blanken, Charlotte F.J.M., Siesling, Sabine, and van Dalen, Thijs

Published
2018

33. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Author

Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, Werkhoven, Erik van, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, Schellens, Jan H M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Henricks, Linda M, Lunenburg, Carin A T C, de Man, Femke M, Meulendijks, Didier, Frederix, Geert W J, Kienhuis, Emma, Creemers, Geert-Jan, Baars, Arnold, Dezentjé, Vincent O, Imholz, Alexander L T, Jeurissen, Frank J F, Portielje, Johanna E A, Jansen, Rob L H, Hamberg, Paul, Ten Tije, Albert J, Droogendijk, Helga J, Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H W, Mandigers, Caroline M P W, Rosing, Hilde, Beijnen, Jos H, Werkhoven, Erik van, van Kuilenburg, André B P, van Schaik, Ron H N, Mathijssen, Ron H J, Swen, Jesse J, Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk-Jan, and Schellens, Jan H M

Published
2018

34. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Author

Apotheek Opleiding, UMC Utrecht, HEE, Child Health, JC onderzoeksprogramma Methodologie, MS Medische Oncologie, Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., Werkhoven, Erik van, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, Schellens, Jan H.M., Apotheek Opleiding, UMC Utrecht, HEE, Child Health, JC onderzoeksprogramma Methodologie, MS Medische Oncologie, Henricks, Linda M., Lunenburg, Carin A.T.C., de Man, Femke M., Meulendijks, Didier, Frederix, Geert W.J., Kienhuis, Emma, Creemers, Geert Jan, Baars, Arnold, Dezentjé, Vincent O., Imholz, Alexander L.T., Jeurissen, Frank J.F., Portielje, Johanna E.A., Jansen, Rob L.H., Hamberg, Paul, ten Tije, Albert J., Droogendijk, Helga J., Koopman, Miriam, Nieboer, Peter, van de Poel, Marlène H.W., Mandigers, Caroline M.P.W., Rosing, Hilde, Beijnen, Jos H., Werkhoven, Erik van, van Kuilenburg, André B.P., van Schaik, Ron H.N., Mathijssen, Ron H.J., Swen, Jesse J., Gelderblom, Hans, Cats, Annemieke, Guchelaar, Henk Jan, and Schellens, Jan H.M.

Published
2018

35. Conventional pathology versus gene signatures for assessing luminal A and B type breast cancers: Results of a prospective cohort study

Author

Pathologie Groep Van Diest, Trialbureau Beeld, Cancer, Pathologie Stafondersteuning, Pathologie, Pathologie Pathologen staf, Cardiovasculaire Epi Team 3, JC onderzoeksprogramma Kanker, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, MS CGO, van Steenhoven, Julia E.C., Kuijer, Anne, van Diest, Paul J., van Gorp, Joost M., Straver, Marieke, Elias, Sjoerd G., Wesseling, Jelle, Rutgers, Emiel, Timmer-Bonte, Johanna N.H., Nieboer, Peter, Smilde, Tineke J., Imholz, Alex, Blanken, Charlotte F.J.M., Siesling, Sabine, van Dalen, Thijs, Pathologie Groep Van Diest, Trialbureau Beeld, Cancer, Pathologie Stafondersteuning, Pathologie, Pathologie Pathologen staf, Cardiovasculaire Epi Team 3, JC onderzoeksprogramma Kanker, MS Reumatologie/Immunologie/Infectie, Infection & Immunity, MS CGO, van Steenhoven, Julia E.C., Kuijer, Anne, van Diest, Paul J., van Gorp, Joost M., Straver, Marieke, Elias, Sjoerd G., Wesseling, Jelle, Rutgers, Emiel, Timmer-Bonte, Johanna N.H., Nieboer, Peter, Smilde, Tineke J., Imholz, Alex, Blanken, Charlotte F.J.M., Siesling, Sabine, and van Dalen, Thijs

Published
2018

36. Metformine: ondanks hoge leeftijd nog springlevend

Author

Brouwers, Koos, Nieboer, Peter, Wilffert, Berend, FarmacoTherapie, -Epidemiologie en -Economie, Methods in Medicines evaluation & Outcomes research, Reproductive Origins of Adult Health and Disease, and Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET)

Abstract

Nieuwe feiten maken dat de rol van metformine nog lang niet is uitgespeeld. Integendeel: door vele nieuwe toepassingen lijkt metformine inmiddels de status van ‘wondermiddel’ te krijgen. Binnen het geweld van dure innovaties is toepassing van en verder onderzoek naar oude en goedkope middelen zoals metformine een goede investering.

Published
2017

37. Conventional Pathology Versus Gene Signatures for Assessing Luminal A and B Type Breast Cancers: Results of a Prospective Cohort Study

Author

van Steenhoven, Julia, primary, Kuijer, Anne, additional, van Diest, Paul, additional, van Gorp, Joost, additional, Straver, Marieke, additional, Elias, Sjoerd, additional, Wesseling, Jelle, additional, Rutgers, Emiel, additional, Timmer-Bonte, Johanna, additional, Nieboer, Peter, additional, Smilde, Tineke, additional, Imholz, Alex, additional, Blanken, Charlotte, additional, Siesling, Sabine, additional, and van Dalen, Thijs, additional

Published
2018
Full Text
View/download PDF

38. High-dose chemotherapy:studies on supportive care, quality of life and late effects of treatment

Author

Nieboer, Peter, Nieboer, Peter, Nieboer, Peter, and Nieboer, Peter

Abstract

Drug resistance is a major problem in the treatment of malignancies. Based on steep dose-response relationship for certain chemotherapeutic drugs in vitro on tumor cell survival, high-dose chemotherapy was considered of interest for the treatment of malignancies. Introduction of autologous bone-marrow toxic chemotherapy while thereafter the bone-marrow was rescued. Initially there were high expectations for the application in solid tumors. Nowadays, following numerous phase 2 and a number of phase 3 studies its precise role in solid tumors is unknown. Therefore, the meta-analysis of especially high-dose chemotherapy in the adjuvant breast cancer setting is eagerly awaited. High-dose chemotherapy induces considerable morbidity. The balance between side effects and survival benefit will finally determine the indication(s) for this treatment modality in solid tumors. This thesis aims to give in depth insight in a number of short-term and long-term side effects that are consequences of high-dose chemotherapy.

Published
2008

39. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3) : a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Author

Simkens, Lieke H J, van Tinteren, Harm, May, Anne, ten Tije, Albert J, Creemers, Geert-Jan M, Loosveld, Olaf J L, de Jongh, Felix E, Erdkamp, Frans L G, Erjavec, Zoran, van der Torren, Adelheid M E, Tol, Jolien, Braun, Hans J J, Nieboer, Peter, van der Hoeven, Jacobus J M, Haasjes, Janny G, Jansen, Rob L H, Wals, Jaap, Cats, Annemieke, Derleyn, Veerle A, Honkoop, Aafke H, Mol, Linda, Punt, Cornelis J A, Koopman, Miriam, Simkens, Lieke H J, van Tinteren, Harm, May, Anne, ten Tije, Albert J, Creemers, Geert-Jan M, Loosveld, Olaf J L, de Jongh, Felix E, Erdkamp, Frans L G, Erjavec, Zoran, van der Torren, Adelheid M E, Tol, Jolien, Braun, Hans J J, Nieboer, Peter, van der Hoeven, Jacobus J M, Haasjes, Janny G, Jansen, Rob L H, Wals, Jaap, Cats, Annemieke, Derleyn, Veerle A, Honkoop, Aafke H, Mol, Linda, Punt, Cornelis J A, and Koopman, Miriam

Published
2015

40. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

Author

Epi Kanker Team 1, Cancer, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Simkens, Lieke H J, van Tinteren, Harm, May, Anne, ten Tije, Albert J, Creemers, Geert-Jan M, Loosveld, Olaf J L, de Jongh, Felix E, Erdkamp, Frans L G, Erjavec, Zoran, van der Torren, Adelheid M E, Tol, Jolien, Braun, Hans J J, Nieboer, Peter, van der Hoeven, Jacobus J M, Haasjes, Janny G, Jansen, Rob L H, Wals, Jaap, Cats, Annemieke, Derleyn, Veerle A, Honkoop, Aafke H, Mol, Linda, Punt, Cornelis J A, Koopman, Miriam, Epi Kanker Team 1, Cancer, JC onderzoeksprogramma Kanker, MS Medische Oncologie, Simkens, Lieke H J, van Tinteren, Harm, May, Anne, ten Tije, Albert J, Creemers, Geert-Jan M, Loosveld, Olaf J L, de Jongh, Felix E, Erdkamp, Frans L G, Erjavec, Zoran, van der Torren, Adelheid M E, Tol, Jolien, Braun, Hans J J, Nieboer, Peter, van der Hoeven, Jacobus J M, Haasjes, Janny G, Jansen, Rob L H, Wals, Jaap, Cats, Annemieke, Derleyn, Veerle A, Honkoop, Aafke H, Mol, Linda, Punt, Cornelis J A, and Koopman, Miriam

Published
2015

41. High-dose chemotherapy: studies on supportive care, quality of life and late effects of treatment

Author

Nieboer, Peter, Mulder, Nanno, de Vries, Liesbeth, Faculteit Medische Wetenschappen/UMCG, and University of Groningen

Subjects
Chemotherapie, Kanker, Bijwerkingen, neoplasmata, gezwellen, Proefschriften (vorm)
Abstract

Drug resistance is a major problem in the treatment of malignancies. Based on steep dose-response relationship for certain chemotherapeutic drugs in vitro on tumor cell survival, high-dose chemotherapy was considered of interest for the treatment of malignancies. Introduction of autologous bone-marrow toxic chemotherapy while thereafter the bone-marrow was rescued. Initially there were high expectations for the application in solid tumors. Nowadays, following numerous phase 2 and a number of phase 3 studies its precise role in solid tumors is unknown. Therefore, the meta-analysis of especially high-dose chemotherapy in the adjuvant breast cancer setting is eagerly awaited. High-dose chemotherapy induces considerable morbidity. The balance between side effects and survival benefit will finally determine the indication(s) for this treatment modality in solid tumors. This thesis aims to give in depth insight in a number of short-term and long-term side effects that are consequences of high-dose chemotherapy.

Published
2008

42. Leprosy and cutaneous leishmaniasis affecting the same individuals: A retrospective cohort analysis in a hyperendemic area in Brazil.

Author

Carvalho, Amanda Gabriela de, Tiwari, Anuj, Luz, João Gabriel Guimarães, Nieboer, Daan, Steinmann, Peter, Richardus, Jan Hendrik, and Ignotti, Eliane

Subjects
CUTANEOUS leishmaniasis, HANSEN'S disease, COHORT analysis, MEDICAL personnel, DISABILITIES
Abstract

Background: Leprosy and cutaneous leishmaniasis (CL) are neglected tropical diseases (NTDs) affecting the skin. Their control is challenging but the integration of skin NTDs control programs is recommended to improve timely detection and treatment. However, little is known about the occurrence of leprosy and CL in the same individuals, and what are the characteristics of such patients. This study aimed to identify and characterize patients diagnosed with both leprosy and CL (i.e., outcome) in the hyperendemic state of Mato Grosso, Brazil. Also, we investigated the demographic risk factors associated with the period between the diagnosis of both diseases. Methodology/principal findings: A retrospective cohort study was conducted with patients diagnosed between 2008 and 2017. From the leprosy (n = 28,204) and CL (n = 24,771) databases of the national reporting system, 414 (0.8%; 414/52,561) patients presenting both diseases were identified through a probabilistic linkage procedure. This observed number was much higher than the number of patients that would be expected by chance alone (n = 22). The spatial distribution of patients presenting the outcome was concentrated in the North and Northeast mesoregions of the state. Through survival analysis, we detected that the probability of a patient developing both diseases increased over time from 0.2% in the first year to 1.0% within seven years. Further, using a Cox model we identified male sex (HR: 2.3; 95% CI: 1.7–2.9) and low schooling level (HR: 1.5; 95% CI: 1.2–1.9) as positively associated with the outcome. Furthermore, the hazard of developing the outcome was higher among individuals aged 40–55 years. Conclusions/significance: Leprosy and CL are affecting the same individuals in the area. Integration of control policies for both diseases will help to efficiently cover such patients. Measures should be focused on timely diagnosis by following-up patients diagnosed with CL, active case detection, and training of health professionals. Author summary: Leprosy and cutaneous leishmaniasis (CL) are neglected tropical diseases (NTDs) that usually affect poor populations in the same geographical areas. Both affect the skin and can cause physical disability and disfigurement resulting in discrimination. Both diseases occur at hyperendemic levels in several regions of Brazil. The integration of skin NTDs control programs may be a way to improve timely detection and treatment. However, little is known about the occurrence of leprosy and CL in the same individuals, and what are the characteristics of these patients. For the Brazilian state of Mato Grosso, we identified 414 patients diagnosed with leprosy and CL between 2008 and 2017, spatially concentrated mainly in the North and Northeast mesoregions. The individual probability of developing both diseases increased from 0.2% to 1.0% within seven years. Male sex, 40–55 years age group, and low levels of schooling were the risk factors positively associated with the time interval between the diagnosis of both diseases. These findings may inform the implementation of integrated leprosy and CL control policies focused on timely diagnosis. A sustainable integration requires continuous measures, such as the follow-up of patients, active case detection, training of health professionals, besides financial and political support. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

43. Comparison of biopsy under‐sampling and annual progression using hidden markov models to learn from prostate cancer active surveillance studies.

Author

Li, Weiyu, Denton, Brian T., Nieboer, Daan, Carroll, Peter R., Roobol, Monique J., and Morgan, Todd M.

Subjects
MARKOV processes, HIDDEN Markov models, PROSTATE cancer, BIOPSY
Abstract

This study aimed to estimate the rates of biopsy undersampling and progression for four prostate cancer (PCa) active surveillance (AS) cohorts within the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium. We used a hidden Markov model (HMM) to estimate factors that define PCa dynamics for men on AS including biopsy under‐sampling and progression that are implied by longitudinal data in four large cohorts included in the GAP3 database. The HMM was subsequently used as the basis for a simulation model to evaluate the biopsy strategies previously proposed for each of these cohorts. For the four AS cohorts, the estimated annual progression rate was between 6%–13%. The estimated probability of a biopsy successfully sampling undiagnosed non‐favorable risk cancer (biopsy sensitivity) was between 71% and 80%. In the simulation study of patients diagnosed with favorable risk cancer at age 50, the mean number of biopsies performed before age 75 was between 4.11 and 12.60, depending on the biopsy strategy. The mean delay time to detection of non‐favorable risk cancer was between 0.38 and 2.17 years. Biopsy undersampling and progression varied considerably across study cohorts. There was no single best biopsy protocol that is optimal for all cohorts, because of the variation in biopsy under‐sampling error and annual progression rates across cohorts. All strategies demonstrated diminishing benefits from additional biopsies. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results